JP2003502365A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003502365A5 JP2003502365A5 JP2001504367A JP2001504367A JP2003502365A5 JP 2003502365 A5 JP2003502365 A5 JP 2003502365A5 JP 2001504367 A JP2001504367 A JP 2001504367A JP 2001504367 A JP2001504367 A JP 2001504367A JP 2003502365 A5 JP2003502365 A5 JP 2003502365A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- ras antagonist
- method described
- geranyl
- fts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 description 25
- 239000005557 antagonist Substances 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000002350 geranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 125000005358 mercaptoalkyl group Chemical group 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000004971 nitroalkyl group Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- WUILNKCFCLNXOK-CFBAGHHKSA-N salirasib Chemical group CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC1=CC=CC=C1C(O)=O WUILNKCFCLNXOK-CFBAGHHKSA-N 0.000 description 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- XNZIHFUAQCUVOU-UHFFFAOYSA-N 2-(4,8,12-trimethyltrideca-3,7,11-trienylsulfanyl)benzoic acid Chemical group CC(C)=CCCC(C)=CCCC(C)=CCCSC1=CC=CC=C1C(O)=O XNZIHFUAQCUVOU-UHFFFAOYSA-N 0.000 description 1
- HHXKLPLAKJMLAI-UHFFFAOYSA-N 2-chloro-5-(3,7,11-trimethyldodeca-2,6,10-trienylamino)benzoic acid Chemical group CC(C)=CCCC(C)=CCCC(C)=CCNC1=CC=C(Cl)C(C(O)=O)=C1 HHXKLPLAKJMLAI-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14019299P | 1999-06-18 | 1999-06-18 | |
| US60/140,192 | 1999-06-18 | ||
| PCT/US2000/016863 WO2000078303A1 (en) | 1999-06-18 | 2000-06-19 | Non-malignant disease treatment with ras antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003502365A JP2003502365A (ja) | 2003-01-21 |
| JP2003502365A5 true JP2003502365A5 (enExample) | 2007-08-02 |
Family
ID=22490144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001504367A Pending JP2003502365A (ja) | 1999-06-18 | 2000-06-19 | Ｒａｓアンタゴニストによる非悪性疾患処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6462086B1 (enExample) |
| EP (1) | EP1187605A4 (enExample) |
| JP (1) | JP2003502365A (enExample) |
| AU (1) | AU5497000A (enExample) |
| CA (1) | CA2377254C (enExample) |
| WO (1) | WO2000078303A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003078448A1 (en) | 2002-03-13 | 2003-09-25 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
| WO2004103352A1 (en) * | 2003-05-23 | 2004-12-02 | Ramot At Tel Aviv University, Ltd. | Ras antagonists for treating neurodegenerative disorders |
| CA2535944A1 (en) * | 2003-08-22 | 2005-03-03 | University Of Virginia Patent Foundation | Blockade of mtor to prevent a hormonal adaptive response |
| US20050216049A1 (en) * | 2004-03-29 | 2005-09-29 | Jones Donald K | Vascular occlusive device with elastomeric bioresorbable coating |
| US7416757B2 (en) * | 2004-04-08 | 2008-08-26 | Cordis Neurovascular, Inc. | Method of making active embolic coil |
| US8338648B2 (en) * | 2004-06-12 | 2012-12-25 | Signum Biosciences, Inc. | Topical compositions and methods for epithelial-related conditions |
| EP2301528B1 (en) * | 2004-08-18 | 2013-04-03 | Kadmon Corporation, LLC | Use of FTS for treating malignant disorders |
| US8221804B2 (en) | 2005-02-03 | 2012-07-17 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| US8278349B2 (en) * | 2005-11-28 | 2012-10-02 | Ramot At Tel-Aviv University Ltd. | Cancer treatment using FTS and 2-deoxyglucose |
| WO2007116396A1 (en) * | 2006-04-11 | 2007-10-18 | Ramot At Tel Aviv University Ltd. | Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor |
| WO2008126094A1 (en) * | 2007-04-17 | 2008-10-23 | Ramot At Tel Aviv University Ltd. | Treatment of myocarditis using fts |
| US20130035390A1 (en) * | 2010-01-13 | 2013-02-07 | Ramot At Tel-Aviv University Ltd. | Treatment of multiple sclerosis |
| WO2012104846A1 (en) * | 2011-01-07 | 2012-08-09 | Ramot At Tel-Aviv University Ltd. | Ras inhibitors for treating diseases or pathological conditions characterized insulin resistance |
| CA2849421C (en) * | 2011-10-07 | 2020-04-28 | Pisces Therapeutics Llc | Malignant and non-malignant disease treatment with ras antagonists |
| US9738614B2 (en) | 2011-10-07 | 2017-08-22 | Pisces Therapeutics, Llc | Malignant and non-malignant disease treatment with Ras antagonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7096194A (en) * | 1993-06-01 | 1994-12-20 | Ludwig Institute For Cancer Research | Fragments of neurofibromin (nf1) and method to reverse activated ras induced malignant transformation in mammalian cells |
| IL107587A (en) * | 1993-11-12 | 1998-08-16 | Univ Ramot | Farnesyl geranyl or geranyl-geranyl derivatives pharmaceutical compositions containing them and methods for their preparation |
| US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| WO1998002436A1 (en) * | 1996-07-15 | 1998-01-22 | Bristol-Myers Squibb Company | Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase |
| DE19644422C2 (de) * | 1996-10-25 | 2000-06-15 | Stefan Schulz | Verwendung von Terpenen zur Behandlung von Autoimmunkrankheiten und bei Transplantat-Abstoßungsreaktionen |
| AU9315698A (en) * | 1997-09-11 | 1999-03-29 | Beth Israel Deaconess Medical Center | (rin2), a novel inhibitor of ras-mediated signaling |
| EP1027042A4 (en) * | 1997-09-29 | 2004-08-18 | Bristol Myers Squibb Co | FARNESYL PROTEIN TRANSFERASE INHIBITORS |
-
2000
- 2000-06-19 US US09/597,332 patent/US6462086B1/en not_active Expired - Lifetime
- 2000-06-19 AU AU54970/00A patent/AU5497000A/en not_active Abandoned
- 2000-06-19 WO PCT/US2000/016863 patent/WO2000078303A1/en not_active Ceased
- 2000-06-19 JP JP2001504367A patent/JP2003502365A/ja active Pending
- 2000-06-19 CA CA002377254A patent/CA2377254C/en not_active Expired - Fee Related
- 2000-06-19 EP EP00939967A patent/EP1187605A4/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003502365A5 (enExample) | ||
| Tiekink | Therapeutic potential of selenium and tellurium compounds: opportunities yet unrealised | |
| JP2009533356A5 (enExample) | ||
| JP2008503484A5 (enExample) | ||
| ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| JP2003506416A5 (enExample) | ||
| ATE517624T1 (de) | Behandlung von neurodegenerativen erkrankungen und krebs im gehirn | |
| GR3005586T3 (enExample) | ||
| RU2003114752A (ru) | Лечение желудочно-кишечных стромальных опухолей | |
| WO2005056524A3 (en) | Therapeutic agents useful for treating pain | |
| JP2013513612A5 (enExample) | ||
| NZ201864A (en) | An antiparkinsonian composition | |
| YU36403A (sh) | Soli izotiazol-4-karboksamida kao anti-hiperproliferacioni agensi | |
| MA27702A1 (fr) | Preparation de suspensions aqueuses steriles comprenant des ingredients actifs cristallins micronises, destinees a l'inhalation | |
| JP2006527185A5 (enExample) | ||
| MY125099A (en) | Comminuted form of (s)-2-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) penyl] propanoic acid | |
| JP2003505419A (ja) | ケトチフェンを含む眼用組成物 | |
| DK1228758T3 (da) | Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom | |
| NO20065078L (no) | Inhaleringspulver formuleringer inneholdende enantiomerisk rene beta-agonister. | |
| UA81640C2 (ru) | Противомикобактериальные соединения, способ их получения, фармацевтическая композиция на их основе | |
| JPH0232023A (ja) | パーキンソン症候群の治療用薬剤 | |
| ZA200704584B (en) | New 3-Phenylpropionic acid derivatives for the treatment of diabetes | |
| JP2005524622A5 (enExample) | ||
| CA2458266A1 (en) | Substituted urea retinoid agonists ii | |
| JP2005525390A5 (enExample) |